A two-phase Phase I trial was conducted to assess the pharmacokinetics of fidaxomicin in healthy subjects receiving single (phase IA) and multiple (phase IB) oral doses. [29] The first phase was a ...

The relative efficacy of Optimer Pharma's investigational antibiotic, fidaxomicin, compared to standard-of-care vancomycin (marketed as Vancocin by drugmaker ViroPharma), remains unclear.

The Institute for Quality and Efficiency in Health Care (IQWiG) has now assessed such additional information for two studies comparing the antibiotic fidaxomicin, which is used for diarrhoea ...

Optimer announced the combined data from its two Phase 3 trials of fidaxomicin for the treatment of patients with Clostridium difficile infection (CDI). The two fidaxomicin clinical studies were ...

Credit: Getty Images. Fidaxomicin is not associated with a shorter length of hospitalization or reduced admission rates among patients with Clostridioides difficile infection compared with vancomycin.

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "DIFICID Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides a detailed picture ...

The tortured road in the discovery and development of Fidaxomicin may shed some light on the obstacles that underline this truism. In the 1980s, the mantra for the discovery of new antibiotics was ...

Last October Cubist Pharmaceuticals (CBST) bought Optimer. Optimer had one drug: fidaxomicin, sold in the US as DIFICID. Cubist paid for the acquisition with a combination of cash and a contingent ...

Optimer Pharmaceuticals Inc. said it will co-market its fidaxomicin drug with Cubist Pharmaceuticals Inc. after winning U.S. panel backing for the antibiotic that fights a deadly bacterium often ...

Louie et al. [45] conducted a randomized, open-label study of the safety and efficacy of fidaxomicin in patients with mild-to-moderately severe CDI. Adults with three or more diarrheal stools ...